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Plasma Metanephrines in the Diagnosis of 
Pheochromocytoma
Jacques W.M. Lenders, MD, PhD; Harry R. Keiser, MD; David S. Goldstein, MD, PhD; 
Jacques J. Willemsen, BS; Peter Friberg, MD, PhD; Marie-Cécile Jacobs, MD;
Peter W.C. Kloppenborg, MD, PhD; Theo Thien, MD, PhD; and Graeme Eisenhofer, PhD
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Objective: To examine whether tests for plasma Pheochromocytoma is a tumor of chromaffin cells that
metanephrines, the o-methylated metabolites of cat- usually presents as hypertension. The tumor has poten-
echolamines, offer advantages for diagnosis of a pheo- tially life-threatening consequences if it is not promptly
chromocytoma over standard tests for plasma cat- diagnosed, located, and removed. Evidence of excessive
echolamines or urinary metanephrines. 
Design: Cross-sectional study. 
Setting: 3 clinical specialist centers.
production of catecholamines is essential for diagnosis of 
the tumor. Traditional tests have relied on measurements 
of the 24-hour urinary excretion of catecholamines (nor-
Patients: 52 patients with a pheochromocytoma; 67 epinephrine and epinephrine) or of the :s of cate-
normotensive persons and 51 patients with essential 
hypertension who provided reference values; and 23 
patients with secondary hypertension and 50 patients 
with either heart failure or angina pectoris who served
cholamine metabolism (1-4).
Because of the common problems of i 
and inconvenience associated with 24-hour urine collec­
tions, clinicians have long sought a diagnostic test based
as comparison groups. on sampling of antecubital venous blood. Measurements
Measurements: Plasma concentrations of cat- of plasma catecholamines are useful in this respect (4, 5).
echolamines (norepinephrine and epinephrine) and However, patients with a pheochromocytoma can have
metanephrines (normetanephrine and metanephrine) plasma concentrations of catecholamines that fall within
were measured in all patients. The 24-hour urinary the range of those in patients with essential hypertension
(4, 6) (that is, false-negative results). In addition, emo­
tional distress or pathologic conditions other than pheo­
chromocytoma (such as heart failure) can produce abnor- 
increases in plasma concentrations of metanephrines mally high catecholamine concentrations (7, 8) (that is, 
that were greater and more consistent than those in false-positive results). Glucagon stimulation and clonidine
excretion of metanephrines was measured in 46 pa­
tients with pheochromocytoma.
Results: Pheochromocytomas were associated with
plasma catecholamine concentrations. No patient with 
a pheochromocytoma had normal plasma concentra-
suppression testing can enhance the accuracy of plasma 
catecholamine determinations in the diagnosis of pheo-
tions of both normetanephrine and metanephrine. The chromocytoma (9, 10). These tests, however, can still yield
sensitivity of these tests was 100% (52 of 52 patients false-negative or false-positive results (9-11);
[95% Cl, 94% to 100%]), and the negative predictive require considerable time and effort. The search has con-
value of normal plasma concentrations of metaneph­
rines was 100% (162 of 162 patients). Tests for plasma
for a single simple, highly sensitive and specific
blood test with which to ■m the presence of the
catecholamines yielded eight false-negative results tumor in patients with pheochromocytoma. We studied
and a sensitivity of 85% (44 of 52 patients [Cl, 72% to the diagnostic accuracy of tests for specific catecholamine
93%]). The negative predictive value of normal plasma metabolites for this purpose, notably the metanephrine»
normetanephrine and metanephrine.
An understanding of why plasma metanephrines may
concentrations of catecholamines was 95% (156 of 164 
patients). Tests for urinary metanephrines yielded five
false-negative results and a sensitivity of 89% (41 of 46 be particularly useful for diagnosis of 
patients [Cl, 76% to 96%]). Because no statistical requires an understanding of catecholamine metabolism, 
difference was noted in the number of false-positive Noreninenhrine and cDincnhrine are first metabolized in­
results between tests for plasma metanephrines (15%) 
and tests for plasma catecholamines (18%), the spec­
ificities of the two tests did not differ.
p p epi ep
traneuronally by deamination to
extraneuronally by omethylation
(12). Because most dihydroxyphenylglycol is formed from
Conclusions: Normal plasma concentrations of meta- norepinephrine leaking from neuronal stores and is
formed from circulating catecholamines (13, 14), plasma 
levels of this metabolite are relatively insensitive to the
of into the circulation from a
nephrines exclude the diagnosis of pheochromocytoma, 
whereas normal plasma concentrations of catechol­
amines and normal urinary excretion of metanephrines 
do not. Tests for plasma metanephrines are more sensi- pheochromocytoma (6, 15). The formation of most mo­
tive than tests for plasma catecholamines or urinary thoxyhydroxyphenylglycol from dihydroxyphenylglycol (14) 
metanephrines for the diagnosis of pheochromocytoma.
Ann Intern Med. 1995:123:101-109.
the formation of most vanillylmandelic acid from 
methoxyhydroxyphenylglycol within the liver (16) explains
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Table 1. Patient Characteristics*
Variable
Patients, n
Mean age ± SD (range), y 
Male/female, n/n
Study center (NIH/SR/SH), n/n/n
Normotension
39 :
Study Group
Secondary
Hypertension
51 2367
h 12 (20-72) 43 ± 13 (16-69) 48 ± 14 (20- 
40/27 
36/31/0
24/27 14/9
1/50/0
Heart Failure or Pheochromocytoma
Angina Pectoris
. . . ( ' « - . . - ( W -  v f ^ j i  “  • s v i - i * - ;  —.. -  - v .  r  « I -- •
50
57 ± 11 (34-81)
42/8 
13/7/30
39
52
t  13 (11-71) 
28/24 
41/11/0
* NIH = National Institutes of Health; SI-1 =  Snhlgrens Hospital; SR = St. Radboud University Hospital.
why a test for vanillylmandelic acid is also a poorer Blood and Urine Samples
marker for pheochromocytoma than other tests (17). In 
contrast, preferential metabolism of circulating catechol­
amines compared with neuronal catecholamines by extra­
neuronal pathways (14) suggests that the metaneph-
All patients refrained from ingesting methylxanthine-contain- 
ing food products and from smoking after midnight on the day 
before blood sampling. Blood was collected from an indwelling 
catheter in an antecubital vein after the patients had rested
rines— as ex traneu rona l m etabolites— may provide good supine for 20 minutes. In 39 patients with heart failure and 15
m arkers  fo r re lease  o f catecholam ines from  a pheochro- with secondary hypertension, arterial blood was obtained through
ail indwelling arm arterial catheter. Blood samples were collected
into precooled tubes containing heparin or EGTA and glutathi
mocytoma. Furthermore, substantial production of meta­
nephrines within adrenal tissue (18) suggests that meta­
nephrines may be produced within the tumor itself.
one and were centrifuged within 30 minutes to separate the 
plasma, which was stored frozen until assayed. All plasma cate-
In hum ans, m e tan ep h rin es  are  extensively sulfate-con- cholamine and urinary metanephrine assays were done within 2
weeks of sample collection. Seven of the 52 pheochromocytoma 
samples were assayed for plasma metanephrines after being 
stored a t - 8 0 ° C  for more than 2 years (range, 2 to 8 years), 
whereas the remaining 45 samples were assayed within 2 years of 
and  conjugated  m etabo lites  (total m etanephrines). In con- collection (22 samples within 4 weeks). In 46 of the 52 patients
trast, good sensitivity o f the  assay for plasm a m etaneph- with pheochromocytoma, a 24-hour urine collection was ob-
jugated (18, 19). Assays of metanephrines in urine depend 
on measurements after deconjugation to free metaneph­
rines (19) so that measurements represent the sum of free
rines (20) enables measurements of both free and total 
metanephrines.
We compared the sensitivity, specificity, and positive 
and negative predictive values of tests for plasma free and 
total metanephrines with those of tests for plasma cat­
echolamines and urinary total metanephrines. Study par­
ticipants included a relatively large sample of patients 
with pheochromocytoma, patients with essential hyperten­
sion or secondary hypertension from causes other than 
pheochromocytoma, and patients with either heart failure 
or angina pectoris in whom sympathetically mediated cat­
echolamine release would be expected to be increased.
tained, with 30 mL of 6-M hydrochloric acid used as a preser-
Methods
Patients
Fifty-two patients with a histologically proven pheochromocy­
toma were studied. Thirty patients were studied retrospectively, 
and 22 were studied before the final diagnosis was made. The 
pheochromocytoma was benign in 39 patients and malignant in
13. Sixty-seven healthy, normotensive persons and 51 patients 
with essential hypertension served as a reference group. Blood 
samples were obtained from 23 patients with secondary hyper­
tension (12 patients with renal artery stenosis, 2 with kidney 
disease, 1 with Cushing disease, 1 with primary hyperaldosteron- 
ism, and 7 with cyelosporine-induced hypertension) and from 50 
patients with either heart failure or angina pectoris. The age, sex, 
and specialty center where the patients were studied for each of 
the five groups are shown in Table 1. Except for the few patients 
who were being treated with phenoxybenzamine, no patients with 
pheochromocytoma had been receiving medication for at least 2 
weeks at the time of blood sampling. No patients with essential 
hypertension had been receiving medication for at least 2 weeks 
at the time of blood sampling. Medications taken by the other 
patient groups included digoxin, calcium channel blockers, di­
uretics, acetylsalicylic acid, dipyridamole, and cyclosporine. Pro­
cedures used in our study were approved by the hospital ethics 
committee or intramural research board of each of the three 
centers where patients were studied.
vative.
Analytic Methods
Plasma metanephrines were assayed at the National Institutes 
of Health (NIH) using liquid chromatography with electrochem­
ical detection (20), Concentrations of total metanephrines (the 
sum of concentrations of free and sulfoconjugated metaneph­
rines) were measured after incubation of 0.25 mL of plasma with 
0.1 units of sulfatase (Sigma Chemical Company, St. Louis, Mis­
souri) at 37 °C for 30 minutes. The detection limits were 0.013 
nmol/L for normetanephrine and 0.019 nmol/L lor metanephrine. 
At a plasma normetanephrine concentration of 0.31 nmol/L and 
a metanephrine concentration of 0.21 nmol/L, the interassay 
coefficients of variation were 12.2% for normetanephrine and 
11.2% for metanephrine. As previously reported (20), the pres­
ence of acetaminophen in samples of plasma can substantially 
interfere with measurements of plasma normetanephrine concen­
trations. Therefore, this analgesic must not be used by patients 
for several days before blood samples are collected. No analytic 
interference of various other drugs with this assay has been 
shown (20).
Plasma catecholamines were assayed using liquid chromatog­
raphy. Electrochemical detection was used for quantification at 
the NIH (21), and fluorometric detection was used at St. Rad­
boud University Hospital, Nijmegen, the Netherlands (22). At 
the NIH, the detection limits were 0.006 nmol/L for norepineph­
rine and 0.010 nmol/L for epinephrine. At a plasma norepineph­
rine concentration of 2.4 nmol/L and an epinephrine concentra­
tion of 0.39 nmol/L, the interassay coefficients of variation were 
6.5% for norepinephrine and 11.4% for epinephrine. At St. Rad­
boud University Hospital, the detection limits for norepinephrine 
and epinephrine were 0.002 nmol/L and 0.003 nmol/L, respec­
tively. At plasma concentrations of 1.02 nmol/L for norepineph­
rine and 0.15 nmol/L for epinephrine, interassay coefficients of 
variation were 8.5% for norepinephrine and 1.2% for epineph­
rine.
Urinary concentrations of metanephrines were measured ac­
cording to a previously described method (23); the upper refer­
ence limit of the normal range for the 24-hour urinaiy output of 
metanephrines was 6.8 umol/d.
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Data Analysis
Because plasma concentrations of catecholamines and meta­
nephrines were not normally distributed, only medians and ranges 
are presented for these concentrations. Différences in plasma 
concentrations of metanephrines and catecholamines among pa­
tients with pheochromocytoma and other groups were tested
using the Kruskal-Wallis test. We assessed relations among vari­
ables using the Spearman rank correlation coefficient.
Normal distributions of plasma concentrations of catechol­
amines and metanephrines were obtained after logarithmic trans­
formation of the data. Thus, upper reference limits, defined as 
the 97.5th percentile, were determined after logarithmic trans­
formation of individual values for the combined data from nor- 
motensive persons and those with essential hypertension (118 
persons). The 97.5th percentiles were calculated from the anti- 
logarithm of the mean plus 2 standard deviations of the trans­
formed data. A false-negative result of a test for plasma meta­
nephrines in a patient with pheochromocytoma was defined as 
plasma concentrations of both normetanephnnes and metaneph­
rines that were below their respective upper reference limits. 
Similarly, a false-negative result of a test for plasma catechol­
amines was defined as plasma concentrations of norepinephrines 
and epinephrines that were below their respective upper refer­
ence limits. A false-positive result of a test for plasma metaneph­
rines in patients without pheochromocytoma was defined as a 
plasma concentration of either normetanephrine or metaneph­
rine that was equal to or above the upper reference limits. 
Similarly, a false-positive result of a test for plasma catechol­
amines was defined as a plasma concentration of either norepi­
nephrine or epinephrine that was equal to or greater than the 
upper reference limits. We calculated the sensitivity and speci­
ficity (with 95% CIs), pretest and post-test probabilities, and 
positive and negative predictive values for each analyte (24).
Differences in tumor-associated elevations in plasma catechol­
amine concentrations and free and total metanephrine concen­
trations were assessed from the fold-increases in plasma concen­
trations of compounds in patients with pheochromocytoma that 
were greater than median values in the normotension and essen­
tial hypertension reference group. We computed mean ± SE 
fold-increases after logarithmic transformation of individual fold- 
increases. We estimated differences among fold-increases by 
analysis of variance; post hoc tests were done with the Seheffe 
F-test.
Receiver-operating characteristic curves were constructed from 
the relation between the rates of true-positive and false-positive 
results (that is, sensitivity compared with 1 minus the specificity) 
for diagnosis of pheochromocytoma that are based on different 
upper reference limits for each analyte (25). These curves en­
abled us to compare the sensitivity and specificity of tests for 
plasma metanephrines for diagnosing pheochromocytoma with 
those of tests for plasma catecholamines, as a function of differ­
ent upper reference limits for each analyte. The areas under the 
receiver-operating characteristic curves for plasma catechol­
amines and metanephrines were calculated as summary measures 
of the diagnostic power that were independent of upper refer­
ence limits. We calculated the difference between the two areas 
and tested them according to the method of Hanley and McNeil 
(26).
Results
Plasma Concentrations of Catecholamines and Free and 
Total Metanephrines
concentrations of free normetanephrine and 
metanephrine in the normotension and hypertension ref­
erence groups were not normally distributed until the 
data were logarithmically transformed (Figure 1). Ranges 
of plasma concentrations of normetanephrine and meta­
nephrine were wider and the values were considerably
* (/>< 0. in patients with pheochromocytoma 
than in any other patient group (Table 2).
In each group, plasma concentrations of total meta-
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Figure 1. The distributions for plasma concentrations of free 
normetanephrine (top) and metanephrine (bottom) arc logarith­
mic transformations of the observed data. The upper reference 
limits, determined from the mean plus 2 standard deviations for 
the combined data from normotensive (NT) patients (n ~  67) 
and those with essential hypertension (EHT) (n ~  51) are shown
by the dashed horizontal lines. CARD = patients with heart 
failure or angina pectoris (n = 50); PM EC) -  patients with pheo- 
chromocytoma (n = 52); SHT = patients with secondary hyper­
tension (n = 23).
nephrines were much higher than concentrations of free 
metanephrines; only a small proportion (<7% ) of the 
normetanephrine or metanephrine in plasma was in the 
free form (Table 2). Like the free metanephrines, ranges 
of plasma concentrations of total metanephrines were
much wider and the values much higher (P < 0.001) in 
patients with pheochromocytoma than in any other pa­
tient group. Similarly, ranges of plasma concentrations of 
norepinephrine and epinephrine were wider in patients 
with pheochromocytoma than in other groups, but only
'ine concentrations were consis 
0.001) in patients with 
other groups.
a than in
Accuracy of Tests for Plasma Metanephrines 
The upper reference limits were 0.66 nmol/L for plasma
normetanephrine and 0.30 nmol/L for
Only 1 of the 52 patients with 
plasma concentration of normetanephrine 
m a I n
had a 
i nor-
). at is, a false-negative result.
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Table 2. Plasma Concentrations of Catecholamines and Metanephrines*
Variable
Normotension
(n = 67)
Essential
Hypertension
(n —  51)
Study Group
Secondary
Hypertension
(n = 23)
Normetanephrine, nmol/L 
Metanephrine, nmol/L
0.27 (0.09-0.70) 0.28 (0.10-0.78) 
0,15 (0.04-0.34) 0.14 (0.06-0.38)
0.26 (0.11-2.24) 
0.21 (0.05-0.93)
Total normetanephrine, nmol/L 6.80 (2.90-24.7) 9.65 (2.90-16.50) 13.71 (3.24-318)
Total metanephrine, nmol/L 
Norepinephrine, nmol/L 
Epinephrine, nmol/L
3.03 (1.25-6.46) 3.98 (0.84-10.90) 4.96 (0.89-69.6)
1.15 (0.42-3.38) 1.38 (0.41-3.58) 
0.09 (0.01-0.36) 0.16 (0.02-0.58)
1.90 (0.77-16.2) 
0.34 (0.04-1.48)
Heart Failure or Pheochromocytoma
Angina Pectoris
(n =  50)
0.32 (0.14-22.47) 
0.22 (0.08-0.51) 
15.46 (4.10-332) 
5.03 (2.42-126)
1.98 (0.29-45.0) 
0.36 (0.04-2.93)
(n = 52)
5.56 (0.48-172) 
0.47 (0.04-382) 
98.9 (14.5-1684) 
7.50 (1.94-329)
11.17 (0.69-1360)
0.23 (0.03-1111)
* Values are expressed as the median (range).
However, this patient (patient 42; Table 3) also had an negative results was reduced from 1 to 0, yielding a sen- 
elevated plasma metanephrine concentration. Thus, when sitivity and negative predictive value of 100% (Table 4). 
both metabolites were considered in the diagnosis rather In 29 of the 191 patients (15%) without pheochromocy- 
than plasma normetanephrine alone, the number of false- toma, a test for plasma normetanephrine or metanephrine
yielded a false-positive result (Figure 2). Six of these 29 
false-positive results were obtained in patients with renal 
artery stenosis or renal failure, and 16 were obtained ina)c
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Figure 2. Relation between plasma concentrations of normeta- 
nephrinc and norepinephrine (top) and between those of meta- 
ncphrine and epinephrine (bottom) in individual patients with 
pheochromocytoma (o) and in patients without pheochromocy-
patients with heart failure.
Accuracy of Tests for Plasma Catecholamines
The upper reference limits were 3.00 nmol/L for nor­
epinephrine and 0.54 nmol/L for epinephrine. In contrast 
to the one patient with pheochromocytoma and a false- 
negative result of the plasma normetanephrine test, 10 
patients had false-negative plasma norepinephrine test re­
sults (Figure 2, top). O f these 10 patients, 2 had elevated 
plasma epinephrine concentrations (patients 32 and 34; 
Table 3); thus, the number of false-negative results was 
reduced from 10 to 8 when the diagnosis was based on 
plasma concentrations of both norepinephrine and epi­
nephrine rather than on norepinephrine concentrations 
alone. This resulted in a sensitivity of 85% (Table 4). 
Tests of plasma catecholamines yielded false-positive re­
sults in 35 (18%) of the 191 patients without pheochro­
mocytoma (Figure 2). In 19 of these 35 patients, results of 
tests for plasma metanephrines were also false-positive. 
Seven of these 35 false-positive results were obtained in 
patients with renal artery stenosis or renal failure, and 21 
were obtained in patients with heart failure.
Accuracy of Tests for Urinary Metanephrines
Twenty-four-hour urine specimens were obtained from 
46 of the 52 patients with pheochromocytoma and were 
not obtained from patients in any other group. The me­
dian urinary excretion rate of metanephrines in 
patients was 24.2 /xmol/d (range, 2.1 to 242 jamol/d). Use 
of an upper reference limit of 6.8 /xmol/d for the urinary 
excretion of metanephrines in normotensive persons (23) 
yielded false-negative results in 5 of the 46 patients and a 
sensitivity of 89% (95% Cl, 76% to 96%); all 5 patients
toma but with false-positive normetanephrine or norepinephrine had increased plasma concentrations of metanephrines,
test results (•). The dashed lines represent the upper reference bu t only 3 had increased plasma concentrations o f cat- 
limits for normetanephrine or metanephrine concentrations (hor­
izontal lines) and norepinephrine or epinephrine concentrations 
(vertical lines), and the gray square bounded by these lines rep-
echolamines. Creatinine excretion among the 5 patients 
with normal urinary excretion of metanephrine was within
resents the normal reference range for concentrations of meta- the normal range (1 to 2.5 g/d). Use of an upper reler-
nephrines and catecholamines. ence limit of 9.5 ¿¿mol/d in hypertensive patients (4)
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Table 3. Neurochemical Characteristics of 11 Patients with Pheochromocytoma and Normal (False-Negative) Plasma 
Concentrations of Norepinephrine or Normetanephrine
Patient Clinical Syndrome Catecholamines Metanephrines
Norepinephrine Epinephrine Normetanephrine Metanephrine
■ . -........  ...........V
i i n i o i / J u  ’ J
14 Sporadic 2.80 0.20 1.03* 0.28
21 Sporadic 2.90 0.36 3.39*f 1.13*t
27 Sporadic 0.69 0.53 1.98*t 9.37*t
32 Sporadic 2.93 0.93"' 4.38*1' 2.31 *t
34 Sporadic 1.73 1.26* 17.19*f I6.52*t
38 Sporadic 2.42 0.17 9.44*1' 0.21
42 Cushing 4.21* 1.61* 0.48 0.55 *
43 von Hippel-Lindau 2.08 0.03 1.69* 0.06
48 Multiple endocrine neoplasia 1.83 0.21 4.10*t 1.40*t
49 Multiple endocrine neoplasia 1.74 0.32 1.28* 3.85*1'
50 von Hippel-Lindau 2.43 0.04 1.71* 0.18
Upper reference limit 3.00 0.54 0.66 0.30
* Denotes a concentration above the upper reference limits, 
t  Denotes a concentration more than threefold above the upper reference limits.
yielded 1.0 false-negative results and a sensitivity of 78% 
(Cl, 64% to 89%).
were elevated more than three times the upper refere 
limits for metanephrines; no patients had elevations in
:ine concentrations
Accuracy of Tests for Plasma Metanephrines Compared 
with Tests for Catecholamines
Tumor-associated elevations in plasma normetaneph­
rine concentrations were 153% greater than those in 
plasma norepinephrine and 64% greater than those in 
plasma concentrations of total normetanephrine (Figure
plasma norepinephrine or
* w <
greater than three times the respective upper 
Limits.
Receiver-operating characteristic curves, which show 
the relation between rates of true-positive and false-pos- 
itive results at different decision thresholds (that is, at 
different upper reference limits of plasma concentrations 
of metanephrines and catecholamines), confirmed the su-
3, top). Tumor-associated elevations in plasma metaneph- periority of tests for plasma metanephrines over tests for
rine concentrations were 70% greater than those in epi­
nephrine concentrations but did not differ from those in 
total metanephrine concentrations (Figure 3, bottom). In­
creases in plasma concentrations of total normetaneph­
rine were 54% greater than increases in plasma concen­
trations of norepinephrine, whereas increases in total 
metanephrine concentrations were 46% greater than in­
creases in epinephrine concentrations.
Among the 11 patients with pheochromocytoma and 
equivocal results of tests for normetanephrine or norepi­
nephrine (Table 3), 17 positive results were obtained for 
tests for metanephrines (normetanephrine, 10 r 
metanephrine, 7 results); only 4 positive results were ob-
•ine, 1tained for tests for 
result; epinephrine, 3 results). In 7 of these 11 patients, 
plasma normetanephrine or metanephrine concentrations
plasma catecholamines for the diagnosis of pheochromo­
cytoma, regardless of the reference limits used to define 
an abnormal test result (Figure 4, top). The area under 
the curve for plasma metanephrines (0.977 ± 0.015) was 
greater than that for plasma catecholamines (0.917 ±
0.027) (P 0.03).
The relation between pretest and post-test probabili-
ties— estimated from the sensitivity and specificity values 
listed in Table 4—show that as the prevalence rate (that 
is, the pretest probabilities) increases, the post-test prob­
abilities similarly increase for diagnoses that are based on 
plasma concentrations of metanephrines and catechol­
amines (Figure 4, bottom). The negative predictive value 
of tests for plasma metanephrines for the diagnosis of
constant at 100% for alla remt
prevalence rates, whereas the negative predictive value of
Table 4. Characteristics of Tests for Plasma Metanephrines and Catecholamines
Variable
• » - J
(95% Cl) Predictive Value
«' .t  ‘ N i f  ^  I .  M  I,  Sbv* . ». ^  ‘• K l ' T * » * 1 - k — — kJ* L V«. «ï!— -C-* :  WM T u l i l J  .-*• •  «>. I« J *, I <L-,> j  I I '«  * • ' -» * *«» i # » / ' *  1 * '^  > '  -■ ~  t i i . r ' i ' A i l  k *  .*■ J  • »*• '  * I  f ' . * '  f  i< > -S.--',- .«V " "  f  i l  I ‘J m .  _ , . i  4
■ M a r a % (n/n) ■ ■ W m M A H W
• i n -----r * ■ m i r i ............. ‘M i M.*k> »  *  -  . .  • a .  s U n M  .  ‘  r  —  f r v *  -A *  •  *-»• •  >r S k  > r« -I •
Metanephrines’" 
Total metanephrines 
Catecholamines
100 (52/52) (94 to 100) 
98 (42/43) (88 to 100) 
85 (44/52) (72 to 93)
85 (162/191) (79 to 90) 
82 (112/137) (74 to 
82 (156/191) (75 to 87)
64 (52/81) 
63 (42/67) 
56 (44/79)
M m
■ M U M «
Predictive Value
. < 1 , .  i . : . i - " " ' , * l B - ' . i . ' , . ' , U . . - J  n - ' f - .  i v i
. . .  k J  I V  •  ______A  V i l a  4 '  I__ _ »  >1  1 1 * 4 ^  *  *  • .  t  I  -  ,  1  • 1 % ^  J* l  V k k . t  I >  •  i“ - ' " 1 ' ' i .  . - f - " - l ,  H ' i l . l l . M i • - v . t n . i - . '  I 4 . : “ •  . K > » . - i i y w  -t— ' .  „ ^ r r t ' T  . n I ■ ■ ■ '< i i  • « l í .  . v ^ , i
100 (162/162)
99(112/113) 
95 (156/164)
* “Metanephrines” refers to free normetanephrine and metanephrine. "Total metanephrines” refers to sullbconjugated and free normetanephrine and 
metanephrine. The sensitivity of (total) metanephrines for diagnosis of pheochromocytoma was calculated from patients with both a false-negative plasma 
(total) normetanephrine test result and a false-negative (total) metanephrine test result, The sensitivity of catecholamines was calculated from patients with 
both a false-negative plasma norepinephrine test result and a false-negative epinephrine test result. The .specificity of (total) metanephrines was calculated 
from patients with either a false-positive plasma (total) normetanephrine test result or a false-positive (total) metanephrine test result. The specificity of 
catecholamines was calculated from patients with either a false-positive plasma norepinephrine lest result or a false-positive plasma epinephrine test result.
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Figure 3. Differences among fold-increascs in plasma concentra­
tions of norepinephrine (NE), normetanephrine (NMN), and to­
tal normetanephrine (top) and differences among fold-increases 
in plasma epinephrine (EPI), metanephrine (MN), and total 
metanephrine (bottom) in patients with pheochromocytoma. 
Fold-increases were estimated from ratios of plasma concentra­
tions of each compound in patients with pheochromocytoma to 
the respective median value for each compound in the reference 
group. Results represent mean ± SE values determined from 
logarithmically transformed values.
(P < 0.05).
tests for plasma catecholamines decreased with increasing 
prevalence rates.
In terms of positive and negative predictive values, 
measurement of plasma concentrations of total normeta­
nephrine and metanephrine provided no advantage over 
measurement of free metanephrine concentrations (Table
Patient and Tumor Characteristics in Relation to 
Neurochemical Indices
Four patients with pheochromocytoma had von Hippel- 
Lindau disease, and six had multiple endocrine neoplasia. 
Two of the patients with von Hippel-Lindau disease had 
normal plasma concentrations of catecholamines but ele­
vated plasma normetanephrine concentrations (patients 
43 and 50; Table 3). One of these patients was asymp­
tomatic; initial testing was done after an adrenal mass was 
noted during computed tomography for an unrelated con­
dition. In this patient, an elevated plasma normetaneph­
rine concentration provided the only other indication for 
a tumor; results of all other neurochemical tests (those 
for plasma catecholamines, urinary metanephrines, clonidine 
suppression, and glucagon stimulation) were negative. Be­
cause of these negative results and for personal reasons, 
the patient did not have surgery until 11 months later. At 
this time, she became symptomatic and had 
plasma concentrations of catecholamines and urinary 
metanephrines in addition to consistently elevated plasma 
concentrations of metanephrines. All patients with multi­
ple endocrine neoplasia were symptomatic, but two had 
normal plasma concentrations of catecholamines (patients 
48 and 49; Table 3). Both these patients had grossly 
elevated plasma concentrations of metanephrines.
In only one patient (patient 42; Table 3) did plasma 
concentrations of metanephrines provide a tumor marker 
that was inferior to that provided by plasma catechol­
amine concentrations. This patient was unusual, present­
ing with Cushing disease secondary to an adrenocortico- 
tropin-secreting pheochromocytoma.
Thirty-two pheochromocytomas were located in the ad­
renal glands, and 19 were located at extra-adrenal sites. 
Patients with the adrenal tumors had higher plasma con­
centrations of metanephrine than patients with extra-ad­
renal tumors (0.61 nmol/L compared with 0.27 nmol/L; 
P = 0.03). Similarly, plasma concentrations of epinephrine 
were higher in patients with adrenal tumors than in those 
with extra-adrenal tumors (0.34 nmol/L compared with 
0.14 nmol/L; P=  0.01). In contrast, plasma concentra­
tions of norepinephrine were higher in patients with ex­
tra-adrenal tumors than in those with adrenal tumors
(22.3 nmol/L compared with 8.40 nmol/L; P 0.009).
Plasma normetan ine concentrations not or
among patients with adrenal and extra-adrenal tumors
(5.83 nmol/L compared with 5.44 nmol/L; P 0.30).
We found strong positive relations between the size of 
the tumor and plasma concentrations of normetanephrine 
(/• = 0.61; P <  0.001), plasma concentrations of metaneph­
rine (r = 0.45; P = 0.007), and urinary excretion of meta­
nephrines (r = 0.64; P < 0.001). No association was seen 
between tumor size and plasma concentrations of norepi-
nephrine (/• = 0.12; P = 0.48) or epinephrine (/• 0 . 14;
P 0.42).
Discussion
Because a pheochromocytoma secretes catecholamines
4). However, measurements of plasma concentrations of directly into the circulation, any of several means to de-
total metanephrines provided greater sensitivity for the tect tumor by assays of sma or urinary cat-
diagnosis of pheochromocytoma than measurements of echolamines and their metabolites should theoretically
plasma concentrations of catecholamines. prove adequate. However, the occurrence of false-nega-
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Figure 4. Receiver-operating characteristic curves (top) and the 
relation between pretest probability (that is, prevalence) and 
post-test probability (bottom). Receiver-operating characteristic 
curves show the relative changes in rates of true-positive and 
false-positive results for the diagnosis of pheochromocytoma as a 
function of different upper reference limits for plasma metaneph­
rines (o) and catecholamines (•). Curves were constructed from 
estimates of the true-positive (sensitivity) and false-positive (1 — 
specificity) rates obtained using upper reference limits deter­
mined from the mean plus 1, 1.5, 2.0, 2.5, 3.0, or 3.5 SDs. The 
different upper reference limits (nmol/L) for plasma catechol­
amines and metanephrines are tabulated below:
1.0 SD
Catecholamines
Norepineph- Epineph- 
-rine rine
1.93 0.24
Metanephrines
Normctancph- Metaneph- 
■rine -rine
0.43 0.21
1.5 SD 2.41 0.36 0.53 0.25
2.0 SD 3.00 0.54 0.66 0.30
2.5 SD 3.75 0.79 0.84 0.37
3.0 SD 4.66 1.18 1.05 0.44
3.5 SD 5.85 Í.76 1.32 0.54
The relation between pretest probability (that is, prevalence) and 
post-test probability shows the effect of prevalence of pheochro­
mocytoma on positive (upper curves) and negative (lower curves) 
predictive values for given test results of plasma metanephrines 
(o) and plasma catecholamines (•).
tive results—normal values in patients with the tumor 
besets most methods for diagnosing pheochromocytoma. 
In particular, reported sensitivities of tests for plasma 
catecholamines have ranged from 67% to 94% (11). In 
our study, 8 of 52 patients with pheochromocytoma had 
normal plasma concentrations of catecholamines, but all 
had elevated concentrations of plasma metanephrines. 
This finding indicates that tests for the latter are more 
sensitive for diagnosis of the tumor than tests for plasma 
catecholamines.
Because no test can be completely sensitive, one may 
ask what our findings of 100% sensitivity and 100% neg­
ative predictive value for tests for plasma metanephrines 
actually mean and in which clinical settings they would 
apply. In our study, 100% sensitivity resulted from the 
consideration of normotensive persons and those with
essential hypertension as a ¡ group
we considered only persons with essential hypertension as
group, one false-negative result
and the sensitivity decreased to 98% (Cl, 90% to
as shown by the receiver-operating characteris­
tic curves, the sensitivity of tests for metanephrines for 
the diagnosis of pheochromocytoma remained higher than 
that of tests for catecholamines, regardless of changes in 
the upper reference limits. For a disease such as pheo­
chromocytoma, in which a missed diagnosis could have 
life-threatening consequences for a patient, the diagnostic 
test should exclude false-negative results as efficiently as 
possible. The results show that measurements of plasma 
concentrations of metanephrines provide a method of 
excluding the presence of a tumor that is superior to 
measurements of plasma catecholamines.
Although pheochromocytoma may be excluded by nor­
mal plasma concentrations of metanephrines, an abnor-
mal test result not the
m
presence of a tumor. We found elevated plasma concen­
trations of metanephrines in a few patients with 
ary hypertension or cardiac failure. Elev 
tions of total metanephrines have also 
patients with renal failure (27). When plasma concentra­
tions of metanephrines are increased in the presence of 
either heart failure or kidney disease, additional diagnos­
tic techniques, including imaging studies, are necessary.
Positive and negative predictive values depend on the 
prevalence or pretest probability of a disease. The pre­
dictive values reported here correspond to a 21% preva­
lence rate of pheochromocytoma—a 
than that in the overall population of patients with hy-
and probably higher than the rate in the hy-
refcrred to most specialist centers. 
The negative predictive value of normal plasma concen-
¡nes was superior to that of normal
jr rate
trations
plasma of prevale ni l,v‘'
(Figure 3, bottom), a disparity that increased with increas­
ing prevalence. Even at the highest prevalence rates, nor­
mal plasma concentrations of metanephrines almost ex­
clude diagnosis of pheochromocytoma. This means that 
in a general practice setting or in patients in whom 
chromocytoma is strongly suspected (for exa
4£at a referral center who have hypertension, headache, 
adrenal mass), normal plasma concentrations of meta­
nephrines may exclude the diagnosis of
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toma, whereas normal plasma concentrations of cat­
echolamines may not.
The additional sensitivity that tests for plasma meta­
rules had no advantage over measurement of free (un­
conjugated) metanephrines. Rather, the presence of a 
tumor causes relatively larger increases in free normeta-
nephrines provide over tests for catecholamines for the nephrine concentrations than in total normetanephrine
detection of a pheochromocytoma may be particularly concentrations. It is the free, not the conjugated, meta-
relevant for persons at increased risk for the tumor be- . nephrines that are produced within chromaffin tissue (un­
cause of a family history of multiple endocrine neoplasia published observations). Thus, although plasma concen-
or von Hippel-Lindau disease. This is shown by the two 
patients with multiple endocrine neoplasia and the two 
patients with von Hippel-Lindau disease in whom plasma 
concentrations of metanephrines, not catecholamines, 
provided evidence for a tumor. In one of the latter pa­
tients, elevated plasma concentrations of metanephrines 
provided the initial diagnosis 11 months before any pré­
traitons of total metanephrines are technically easier to 
measure than plasma concentrations of free metaneph­
rines, the latter yield superior results.
Consistent with findings in previous studies (2, 11), 
measurement of urinary metanephrines yielded false-neg­
ative results in a few patients. Why would a test for 
urinary metanephrines be less sensitive than a test for
senting symptom. Although this finding is promising, the plasma concentrations of the same compounds? One ex­
helpfulness of plasma concentrations of metanephrines in planation is that a small percentage of patients in any
large-scale study would be expected to provide an incom­
plete urine collection; this would yield false-negative re-
However, the normal creatinine excretion in the 
A limitation of our study is the lack of a reference patients with false-negative results of tests for urinary
screening asymptomatic persons with hereditary endocrine 
syndromes remains to be established by 
larger samples of such patients.
group of patients with a panic disorder syndrome; a di- metanephrines rules out this explanation. Another possi-
agnosis of pheochromocytoma in patients must ble explanation is that the assay technique used (23) is a
sometimes be excluded (28). Stress-induced elevations of 
plasma catecholamines in these patients may present a 
diagnostic challenge. Because mild mental stress causes 
little change in plasma concentrations of metanephrines 
despite significant increases in plasma catecholamine con­
centrations (18), measurements of plasma concentrations 
of metanephrines may be particularly useful for excluding 
pheochromocytoma in patients with a panic disorder.
Greater and more consistent tumor-associated increases
colorimetric method. An assay for urinary metanephrines 
that uses the high-performance liquid chromatography 
technique might be superior to the colorimetric tech­
nique. Finally, individual differences in the renal conver­
sion of metanephrines to methoxyhydroxyphenylglycol and 
vanillylmandelic acid might be responsible for some of the 
false-negative results.
Plasma catecholamines were assayed at two centers, 
whereas plasma metanephrines were assayed at one cen-
in plasma concentrations of metanephrines than in cate- ter. The involvement of different laboratories in our study 
cholamine concentrations explain the better sensitivity of could have resulted in wider distributions and higher up- 
the test for the former for diagnosing pheochromocytoma. per reference limits for plasma catecholamines than might
Intravenous infusion of catecholamines results in in­
creases in plasma concentrations of metanephrines that 
are less than 6% of those of the precursor amines (18). 
Thus, metabolism of catecholamines after they are re­
leased by a tumor into the circulation is not responsible 
for the greater and more consistent increases in plasma 
concentrations of metanephrines compared with those in 
catecholamine concentrations in patients with a pheochro- 
mocytoma. The production of 90% of plasma metaneph- 
rine and as much as 40% of plasma normetanephrine 
from metabolism of catecholamines within the adrenal
have been obtained had measurements been done in one 
laboratory. This in turn could have resulted in more false- 
negative results for plasma catecholamines determined in 
two laboratories than would have occurred in one. How­
ever, separate analysis of the data for the two centers 
indicated a 14.6% rate of false-negative results for cat­
echolamines assayed at St. Radboud University Hospital 
compared with 18.2% for those assayed at NII-I. In addi­
tion, the reference limits of 3.00 nmol/L for norepineph­
rine and 0.54 nmol/L for epinephrine obtained in our 
study were substantially lower than those of other studies
glands (18, 29) suggests that metanephrines are produced (4, 6, 10). Because many of the patients with equivocal
within the tumor itself. This conclusion is supported by catecholamine test results had plasma concentrations of
observations of high tumor-tissue concentrations of meta- catecholamines well below the upper reference limits, a
nephrines (30, 31) and high plasma normetanephrine con- substantial reduction in these limits would be required to
centrations in the venous effluent of pheochromocytomas influence the results.
(32). The conclusion is also supported by our findings In conclusion, normal plasma concentrations of meta-
reported here and elsewhere (33) that tumor size is a nephrines exclude a diagnosis of pheochromocytoma, and 
determinant of metabolite production but not of catechol- normal plasma catecholamines or urinary metanephrines 
amine release. Thus, even when pheochromocytomas are do not. Tests for plasma metanephrines are more sensi- 
quiescent and are not releasing catecholamines, they ap- tive than tests for plasma catecholamines or urinary meta­
pear to be actively metabolizing catecholamines to meta- nephrines for the diagnosis of pheochromocytoma. 
nephrines.
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